AU2010233187B2 - Methods for preventing and/or treating degenerative disorders of the central nervous system - Google Patents

Methods for preventing and/or treating degenerative disorders of the central nervous system Download PDF

Info

Publication number
AU2010233187B2
AU2010233187B2 AU2010233187A AU2010233187A AU2010233187B2 AU 2010233187 B2 AU2010233187 B2 AU 2010233187B2 AU 2010233187 A AU2010233187 A AU 2010233187A AU 2010233187 A AU2010233187 A AU 2010233187A AU 2010233187 B2 AU2010233187 B2 AU 2010233187B2
Authority
AU
Australia
Prior art keywords
piperidine
diol
compound
comprises administering
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010233187A
Other languages
English (en)
Other versions
AU2010233187A1 (en
Inventor
Robert Boyd
Gary Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of AU2010233187A1 publication Critical patent/AU2010233187A1/en
Application granted granted Critical
Publication of AU2010233187B2 publication Critical patent/AU2010233187B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010233187A 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system Ceased AU2010233187B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16810109P 2009-04-09 2009-04-09
US61/168,101 2009-04-09
PCT/US2010/030470 WO2010118282A1 (en) 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system

Publications (2)

Publication Number Publication Date
AU2010233187A1 AU2010233187A1 (en) 2011-11-03
AU2010233187B2 true AU2010233187B2 (en) 2015-10-08

Family

ID=42934882

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010233187A Ceased AU2010233187B2 (en) 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system

Country Status (11)

Country Link
US (1) US8304429B2 (enExample)
EP (1) EP2416655B1 (enExample)
JP (1) JP5634498B2 (enExample)
CN (1) CN102448306B (enExample)
AU (1) AU2010233187B2 (enExample)
BR (1) BRPI1015472A2 (enExample)
CA (1) CA2758187C (enExample)
ES (1) ES2505243T3 (enExample)
IL (1) IL215584A (enExample)
NZ (1) NZ595630A (enExample)
WO (1) WO2010118282A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2758271C (en) * 2009-04-09 2018-06-05 Robert Boyd Methods for preventing and/or treating lysosomal storage disorders
RU2015147509A (ru) 2009-10-19 2019-01-14 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
EP2490533B1 (en) * 2009-10-19 2015-09-16 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
EP3521451A1 (en) 2010-11-17 2019-08-07 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2013070981A2 (en) * 2011-11-08 2013-05-16 University Of Central Florida Research Foundation, Inc. Treating er stress related disorders by stabilizing intracellular calcium homeostasis
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
EP3087056A4 (en) 2013-12-23 2017-07-19 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
MX2019002673A (es) * 2016-09-12 2019-07-04 Hoffman Steven Composiciones y metodos para tratar demencia.
JP7217229B2 (ja) * 2016-11-15 2023-02-02 ハー・ルンドベック・アクチエゼルスカベット シヌクレイノパチーの治療のための薬剤、使用および方法
WO2019140231A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
AU2019208011B2 (en) 2018-01-12 2025-06-05 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN119606967B (zh) * 2024-12-13 2025-09-05 合肥工业大学 氯雷他定在制备用于预防和治疗血管钙化药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024391A1 (en) * 1994-03-09 1995-09-14 Novo Nordisk A/S Piperidines and pyrrolidines
WO2004037233A2 (en) * 2002-10-28 2004-05-06 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002306848A1 (en) * 2001-03-23 2002-10-08 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6670625B1 (en) * 2002-06-18 2003-12-30 Ge Medical Systems Global Technology Company, Llc Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
KR101402554B1 (ko) * 2006-06-23 2014-06-19 아미쿠스 세라퓨틱스, 인코포레이티드 β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법
US20080009156A1 (en) 2006-07-10 2008-01-10 Malin Glen K System and method for bonding coaxial cable
CA2758271C (en) * 2009-04-09 2018-06-05 Robert Boyd Methods for preventing and/or treating lysosomal storage disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024391A1 (en) * 1994-03-09 1995-09-14 Novo Nordisk A/S Piperidines and pyrrolidines
WO2004037233A2 (en) * 2002-10-28 2004-05-06 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases

Also Published As

Publication number Publication date
CN102448306B (zh) 2014-07-02
JP5634498B2 (ja) 2014-12-03
WO2010118282A1 (en) 2010-10-14
CA2758187C (en) 2017-03-07
NZ595630A (en) 2013-04-26
CA2758187A1 (en) 2010-10-14
ES2505243T3 (es) 2014-10-09
EP2416655B1 (en) 2014-06-25
IL215584A0 (en) 2011-12-29
HK1168005A1 (zh) 2012-12-21
US20100261753A1 (en) 2010-10-14
AU2010233187A1 (en) 2011-11-03
CN102448306A (zh) 2012-05-09
BRPI1015472A2 (pt) 2015-11-24
EP2416655A1 (en) 2012-02-15
US8304429B2 (en) 2012-11-06
IL215584A (en) 2016-11-30
JP2012523430A (ja) 2012-10-04
EP2416655A4 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
AU2010233187B2 (en) Methods for preventing and/or treating degenerative disorders of the central nervous system
AU2017272296B2 (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
JP5645918B2 (ja) リソソーム蓄積障害の予防および／または治療方法
HK1168005B (en) Methods for preventing and/or treating degenerative disorders of the central nervous system
HK1235628A (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
HK1235628B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
HK1235628A1 (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
HK1175074A (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired